MinervaX
Cambridge, United States· Est.
MinervaX is developing a novel vaccine for Group B Streptococcus to prevent infections in newborns and adults.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $126M
About
MinervaX is developing a novel vaccine for Group B Streptococcus to prevent infections in newborns and adults.
VaccinesInfectious Disease
Funding History
2Total raised:$126M
Venture$54M
Venture$72M